Knowing your cardiovascular risk is only as good as the tools used to measure it. The AHA's 2023 PREVENT equations replaced the older Pooled Cohort Equations as the standard method for estimating 10-year atherosclerotic cardiovascular disease (ASCVD) risk — but a critical question remained: does adding a coronary artery calcium (CAC) score on top of PREVENT meaningfully improve risk prediction for individual adults?
This observational cohort study, published in JAMA, examined whether incorporating CAC scoring improved the predictive utility of the PREVENT equations beyond traditional risk factors alone. The investigators evaluated reclassification and discrimination metrics — including C-statistics and net reclassification improvement — across a multi-cohort population of adults without established cardiovascular disease. The findings indicate that CAC addition produced statistically meaningful improvements in risk stratification, particularly in intermediate-risk individuals who are the hardest to classify correctly using clinical variables alone. Adults with a CAC score of zero were consistently reclassified downward into lower risk categories, while those with elevated calcium burden were reclassified upward, directly influencing statin and preventive therapy decisions.
This work matters because PREVENT already incorporates kidney function and metabolic variables absent from older equations, making it a stronger baseline. The fact that CAC still adds incremental value on top of this more comprehensive model is notable — it suggests that imaging-derived atherosclerotic burden captures biological risk dimensions that no blood test or clinical measurement can fully replicate. For the estimated 20–30% of adults who fall in the intermediate risk band where treatment decisions are genuinely uncertain, a CAC scan may provide the tiebreaker that shifts clinical management. The study's observational design limits causal inference, and long-term outcome data will be needed to confirm whether PREVENT-plus-CAC reclassification translates into improved patient outcomes rather than just better statistics. Still, for health-conscious adults approaching midlife discussions about statin initiation, this finding strengthens the case for CAC scoring as a practical, low-radiation decision aid.